{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:55:06Z","timestamp":1791478506520,"version":"4.3.4"},"reference-count":43,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n The US opioid crisis is currently driven by illicitly manufactured fentanyl combined with an evolving mix of stimulants and adulterants, such as the veterinary sedative xylazine, which further complicate clinical and public health responses. Using urine drug testing (UDT) to understand changes in the geographic spread and relative concentration of xylazine over time may provide clarity on the changing dose of exposure for xylazine and future emerging adulterants.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To differentiate spatiotemporal trends in xylazine detection and relative concentration in UDT specimens from 2023 to 2025.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cross-sectional study analyzed UDT specimens collected from US patients (1 specimen per patient) aged 18 years or older from March 2023 and September 2025. Tests were ordered by behavioral health, primary care, or substance use treatment practitioners. If more than 1 specimen was provided by a patient during the study period, only the first specimen collected was included. Data were analyzed from June to September 2025.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n UDT specimens were analyzed for fentanyl and xylazine (primary exposure) using liquid chromatography with tandem mass spectrometry. Specimens were included in the study if fentanyl was detected.<\/jats:p>\n <\/jats:sec>\n \n Main Outcome and Measures<\/jats:title>\n Differences in xylazine positivity by patient and practitioner characteristics, copositivity for other substances, and fentanyl concentration were assessed using logistic regression. Spatiotemporal trends in monthly percentages of xylazine positivity and concentration in UDT, stratified by East and West Census regions, are described.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 42\u202f307 specimens (24\u202f339 [57.52%] from male patients; 15\u202f583 [36.83%] from patients aged 26-35 years) were analyzed. In both regions, xylazine detection increased between the first and last months (East: 8.52 percentage points [from 11.11% to 19.63%]; West 13.46 percentage points [from 0.0% to 13.46%]) while concentration decreased (East: \u221237.76 ng xylazine per 1 mg creatinine [from 61.77 to 24.00 ng xylazine per 1 mg creatinine]; West: \u22127.98 ng xylazine per 1 mg creatinine [from 28.62 to 20.64 ng xylazine per 1 mg creatinine]). Odds of xylazine detection were 79% lower in the West (AOR vs East, 0.21 [95% CI, 0.19 to 0.22];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001), and 120% higher in samples with heroin positivity (AOR vs heroin negativity, 2.20 [95% CI, 2.07 to 2.35];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001) or with higher fentanyl concentrations (AOR per 10-fold increase, 1.55 [95% CI, 1.53 to 1.57];\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cross-sectional study of xylazine-fentanyl in UDT specimens, xylazine detection increased but concentration decreased over time. These findings suggest UDT complements existing drug surveillance and provides unique insights into emerging fentanyl adulterants.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.22473","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:29Z","timestamp":1783609229000},"page":"e2622473","source":"Crossref","is-referenced-by-count":1,"title":["Xylazine-Fentanyl Positivity and Concentration in Urine Drug Tests"],"prefix":"10.1001","volume":"9","author":[{"given":"Olivia K.","family":"Sugarman","sequence":"first","affiliation":[{"name":"Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Marks","sequence":"additional","affiliation":[{"name":"Millennium Health, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Penn","family":"Whitley","sequence":"additional","affiliation":[{"name":"Millennium Health, San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Saloner","sequence":"additional","affiliation":[{"name":"Department of Health Services, Policy, and Practice, Brown University School of Public Health, Providence, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"German","sequence":"additional","affiliation":[{"name":"Department of Health, Behavior, and Society, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,7,9]]},"reference":[{"issue":"8","key":"zoi260624r2","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.2105\/AJPH.2022.306881","article-title":"Xylazine and overdoses: trends, concerns, and recommendations.","volume":"112","author":"Alexander","year":"2022","journal-title":"Am J Public Health"},{"key":"zoi260624r3","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2025.101075","article-title":"Spatiotemporal analysis of substance use disorder mortality in the United States: an observational study of emerging hotspots and vulnerable populations (2005-2020).","volume":"45","author":"Escobar","year":"2025","journal-title":"Lancet Reg Health Am"},{"issue":"26","key":"zoi260624r5","doi-asserted-by":"publisher","first-page":"721","DOI":"10.15585\/mmwr.mm7226a4","article-title":"Illicitly manufactured fentanyl-involved overdose deaths with detected xylazine\u2014United States, January 2019-June 2022.","volume":"72","author":"Kariisa","year":"2023","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"zoi260624r6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s13181-025-01104-6","article-title":"The Donovan Memorial Lecture: \u2018fentanyl-plus\u2019: a new era of fentanyl polydrug combinations in the North American overdose crisis.","volume":"22","author":"Ciccarone","year":"2026","journal-title":"J Med Toxicol"},{"key":"zoi260624r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109380","article-title":"Xylazine spreads across the US: a growing component of the increasingly synthetic and polysubstance overdose crisis.","volume":"233","author":"Friedman","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi260624r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.forsciint.2014.03.015","article-title":"Xylazine intoxication in humans and its importance as an emerging adulterant in abused drugs: a comprehensive review of the literature.","volume":"240","author":"Ruiz-Col\u00f3n","year":"2014","journal-title":"Forensic Sci Int"},{"issue":"1","key":"zoi260624r9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1747-597X-6-7","article-title":"Xylazine (veterinary sedative) use in Puerto Rico.","volume":"6","author":"Torruella","year":"2011","journal-title":"Subst Abuse Treat Prev Policy"},{"issue":"1","key":"zoi260624r12","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1097\/ADM.0000000000001474","article-title":"The Detection of xylazine in Tijuana, Mexico: triangulating drug checking and clinical urine testing data.","volume":"20","author":"Friedman","year":"2026","journal-title":"J Addict Med"},{"issue":"1","key":"zoi260624r13","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/s12954-024-00940-z","article-title":"Reported xylazine exposure highly associated with overdose outcomes in a rapid community assessment among people who inject drugs in Baltimore.","volume":"21","author":"German","year":"2024","journal-title":"Harm Reduct J"},{"issue":"2","key":"zoi260624r14","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1097\/ADM.0000000000001383","article-title":"Personal experiences with xylazine and behavior change: a qualitative content analysis of Reddit posts.","volume":"19","author":"Heidari","year":"2025","journal-title":"J Addict Med"},{"issue":"6","key":"zoi260624r15","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1097\/ADM.0000000000001216","article-title":"Self-reported Xylazine experiences: a mixed-methods study of Reddit subscribers.","volume":"17","author":"Spadaro","year":"2023","journal-title":"J Addict Med"},{"issue":"4","key":"zoi260624r17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1111\/add.16388","article-title":"Clinical considerations for the management of xylazine overdoses and xylazine-related wounds.","volume":"119","author":"Sue","year":"2024","journal-title":"Addiction"},{"issue":"6","key":"zoi260624r18","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/ajad.70051","article-title":"Management of xylazine toxicity, overdose, dependence, and withdrawal: a systematic review.","volume":"34","author":"Owusu-Antwi","year":"2025","journal-title":"Am J Addict"},{"issue":"3","key":"zoi260624r19","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.jhsa.2024.11.017","article-title":"The management of upper-extremity xylazine-associated wounds.","volume":"50","author":"Johnsen","year":"2025","journal-title":"J Hand Surg Am"},{"issue":"1","key":"zoi260624r20","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1001\/jamadermatol.2024.4253","article-title":"Wound characteristics among patients exposed to xylazine.","volume":"161","author":"Lutz","year":"2025","journal-title":"JAMA Dermatol"},{"key":"zoi260624r21","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.112390","article-title":"Drug use practices and wound care experiences in the age of xylazine adulteration.","volume":"263","author":"Jawa","year":"2024","journal-title":"Drug Alcohol Depend"},{"issue":"10","key":"zoi260624r23","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1080\/15563650.2025.2529016","article-title":"Xylazine detection in urine of fentanyl-positive patients from a single academic center.","volume":"63","author":"Leal Lopez","year":"2025","journal-title":"Clin Toxicol (Phila)"},{"issue":"20","key":"zoi260624r24","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1080\/17576180.2025.2572959","article-title":"Recent advances in the identification and quantification of xylazine and medetomidine in biological specimens.","volume":"17","author":"Crews","year":"2025","journal-title":"Bioanalysis"},{"issue":"6","key":"zoi260624r27","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15425","article-title":"Analysis of urine drug test results from substance use disorder treatment practices and overdose mortality rates, 2013-2020.","volume":"5","author":"Whitley","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"10","key":"zoi260624r28","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.41063","article-title":"Fentanyl, heroin, methamphetamine, and cocaine analyte concentrations in urine drug testing specimens.","volume":"7","author":"Huhn","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"6","key":"zoi260624r29","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.14402","article-title":"Generating timely estimates of overdose deaths for the US using urine drug test data.","volume":"8","author":"Myers","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"3","key":"zoi260624r31","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1097\/ADM.0000000000000323","article-title":"Appropriate Use of Drug Testing in Clinical Addiction Medicine.","volume":"11","author":"Jarvis","year":"2017","journal-title":"J Addict Med"},{"issue":"2","key":"zoi260624r32","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1093\/clinchem\/hvae163","article-title":"Xylazine pharmacokinetics in patients testing positive for fentanyl and xylazine.","volume":"71","author":"Lin","year":"2025","journal-title":"Clin Chem"},{"key":"zoi260624r36","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2025.105017","article-title":"A brick to a bundle: a qualitative study of behavioral responses to xylazine adulteration.","volume":"145","author":"Sibley","year":"2025","journal-title":"Int J Drug Policy"},{"key":"zoi260624r37","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104472","article-title":"A content analysis of legal policy responses to xylazine in the illicit drug supply in the United States.","volume":"129","author":"Sugarman","year":"2024","journal-title":"Int J Drug Policy"},{"key":"zoi260624r39","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001592","article-title":"The shifting landscape of a fentanyl adulterant: moving from xylazine to medetomidine.","author":"Huo","year":"2025","journal-title":"J Addict Med"},{"key":"zoi260624r40","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2025.100364","article-title":"Xylazine prevalence and concentration in the Los Angeles fentanyl market, 2023-2025.","volume":"16","author":"Friedman","year":"2025","journal-title":"Drug Alcohol Depend Rep"},{"issue":"24","key":"zoi260624r41","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1056\/NEJMp2303120","article-title":"Xylazine\u2014medical and public health imperatives.","volume":"388","author":"Gupta","year":"2023","journal-title":"N Engl J Med"},{"issue":"3","key":"zoi260624r43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1089\/hs.2022.0150","article-title":"Establishing an approach for designation of evolving and emerging drug threats.","volume":"21","author":"Ashburn","year":"2023","journal-title":"Health Secur"},{"key":"zoi260624r1","unstructured":"Centers for Disease Control and Prevention. Understanding the opioid overdose epidemic. Updated November 1, 2024. Accessed December 3, 2024. https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html"},{"key":"zoi260624r4","unstructured":"Midgette? G, Reuter? P. The dynamics of US drug markets. 2024. Accessed December 18, 2025. https:\/\/www.brookings.edu\/wp-content\/uploads\/2024\/11\/FP-20241127-drug-markets-midgette-reuter.pdf"},{"key":"zoi260624r10","unstructured":"Drug Enforcement Administration. 2025 National Drug Threat Assessment. Published May 2025. Accessed December 18, 2025. https:\/\/www.dea.gov\/sites\/default\/files\/2025-07\/2025NationalDrugThreatAssessment.pdf"},{"key":"zoi260624r11","unstructured":"Drug Enforcement Administration. Xylazine information. Updated October 30, 2024. Accessed December 10, 2025. https:\/\/www.dea.gov\/xylazine-information"},{"key":"zoi260624r16","unstructured":"Drug Enforcement Administration. The growing threat of xylazine and its mixture with illicit drugs. Published October 2022. Accessed December 10, 2025. https:\/\/www.dea.gov\/sites\/default\/files\/2022-12\/The%20Growing%20Threat%20of%20Xylazine%20and%20its%20Mixture%20with%20Illicit%20Drugs.pdf"},{"key":"zoi260624r22","unstructured":"Department of Public Health: City of Philadelphia. Recommendations for caring for individuals with xylazine-associated wounds. Published January 8, 2024. Accessed December 10, 2025. https:\/\/hip.phila.gov\/document\/4148\/Recommendations_for_Caring_for_People_with_Xylazine-Associated_Wounds_1.12.pdf\/"},{"key":"zoi260624r25","unstructured":"Millenium Health. Xylazine spreads west in year following emerging threat designation. Published July 2024. Accessed September 20, 2024. https:\/\/www.millenniumhealth.com\/wp-content\/uploads\/2024\/07\/Xylazine-Signals-Alert.pdf"},{"key":"zoi260624r26","unstructured":"Millennium Health. Zeroing in on Xylazine: The First 100 Days after U.S. Emerging Threat Designation. Published 2023. Accessed September 20, 2024. https:\/\/resource.millenniumhealth.com\/signalsreportxylazine"},{"key":"zoi260624r30","unstructured":"Millennium Health. Drug testing laboratory. Accessed December 19, 2025. https:\/\/www.millenniumhealth.com\/for-clinicians\/our-laboratory\/"},{"key":"zoi260624r33","unstructured":"Centers for Disease Control and Prevention. Geographic division or region. Updated July 30, 2024. Accessed April 14, 2026. https:\/\/www.cdc.gov\/nchs\/hus\/sources-definitions\/geographic-region.htm"},{"key":"zoi260624r34","unstructured":"US Census Bureau. Census regions and divisions of the United States. Accessed April 14, 2026. https:\/\/www2.census.gov\/geo\/pdfs\/maps-data\/maps\/reference\/us_regdiv.pdf"},{"key":"zoi260624r35","unstructured":"Centers for Disease Control and Prevention. HIV risk, prevention, and testing behaviors among persons who inject drugs. Published March 31, 2026. Accessed April 15, 2026. https:\/\/www.cdc.gov\/hiv-data\/nhbs\/hiv-risk-prevention-testing-pwid.html"},{"key":"zoi260624r38","unstructured":"Avilucea? I. New drug emerges in Philly\u2019s drug supply as xylazine use falls. Axios. April 3, 2025. Accessed December 18, 2025. https:\/\/www.axios.com\/local\/philadelphia\/2025\/04\/03\/xylazine-decline-new-drug-philly-medetomidine"},{"key":"zoi260624r42","unstructured":"Centers for Disease Control and Prevention. SUDORS Dashboard: fatal drug overdose data. Updated December 3, 2025. Accessed December 10, 2025. https:\/\/www.cdc.gov\/overdose-prevention\/data-research\/facts-stats\/sudors-dashboard-fatal-overdose-data.html"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2851452\/sugarman_2026_oi_260624_1782932619.50251.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T15:00:31Z","timestamp":1783609231000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2851452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,9]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.22473","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,9]]}}}